AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1589135 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride (75 mg die per os)
Number of subjects: 50
Study 1589135 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (30 mg die per os)
Number of subjects: 50
Study 6112039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol (beta agonist with vasodilator and positive inotropic properties)
Number of subjects: 59
Study 6112039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of pirbuterol
Number of subjects: 59
Study 6112039 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental doses of pirbuterol
Number of subjects: 59
Study 6112039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol
Number of subjects: 59
Study 30516414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush
Number of subjects: 44
Study 30516414 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush
Number of subjects: 44
Study 27842315 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2, 0.1, and 0.1 mg/kg i.v. every 24 h for 3 doses)
Number of subjects: 144
Study 27842315 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen lysine (10, 5, and 5 mg/kg i.v. every 24 h for 3 doses)
Number of subjects: 144
Study 27842315 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 144
Study 27842315 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 144
Study 25873151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer and conventional exercises
Number of subjects: 0
Study 25873151 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 0
Study 22797979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 1.0 M
Number of subjects: 72
Study 22797979 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine 0.5 M
Number of subjects: 72
Study 21286719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy concurrent with radiotherapy
Number of subjects: 81
Study 19038534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day (immediate initiation with simultaneous discontinuation of olanzapine/risperidone)
Number of subjects: 269
Study 19038534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day (immediate initiation while tapering off olanzapine/risperidone over 14 days)
Number of subjects: 269
Study 19038534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day (titrating upwards while tapering off olanzapine/risperidone over 14 days)
Number of subjects: 269
Study 19038534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day (all groups)
Number of subjects: 269
Study 17940371 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy
Number of subjects: 0
Study 17940371 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 0
Study 17940371 — intervention group
Group type: COMPARATOR
Intervention: Resection plus postoperative chemoradiotherapy
Number of subjects: 0
Study 17198261 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg plus full-dose cyclosporine (FDC)
Number of subjects: 696
Study 17198261 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) plus full-dose cyclosporine (FDC)
Number of subjects: 696
Study 17198261 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5 mg plus reduced-dose cyclosporine (RDC)
Number of subjects: 696
Study 17198261 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg plus FDC
Number of subjects: 696
Study 12697283 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation (360 mg daily for 4 weeks)
Number of subjects: 28
Study 10521100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg i.m. dose of triptorelin
Number of subjects: 53
Study 10521100 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 53
Study 7595707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM; 20 mg/d)
Number of subjects: 648
Study 7595707 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR; 60 mg/d)
Number of subjects: 648
Study 7595707 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR; 200 mg/d)
Number of subjects: 648
Study 7595707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 648
Study 2196954 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a grommet (with or without adenoidectomy and myringotomy)
Number of subjects: 127
Study 2196954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with myringotomy and grommet insertion
Number of subjects: 127
Study 2196954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 127
Study 2196954 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy and grommet insertion (without adenoidectomy)
Number of subjects: 127
Study 2196954 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 127
Study 6161320 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)Deprenyl 10 mg daily for 4 weeks
Number of subjects: 11
Study 6161320 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)Deprenyl
Number of subjects: 11
Study 6161320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29792519 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physician reviews endorsing technical skills of a female PCP
Number of subjects: 0
Study 29792519 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physician reviews endorsing technical skills of a male PCP
Number of subjects: 0
Study 29792519 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physician reviews endorsing interpersonal skills
Number of subjects: 0
Study 29792519 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physician reviews endorsing technical skills
Number of subjects: 0
Study 28202404 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rhC1-INH 50 U/kg
Number of subjects: 16
Study 28202404 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rhC1-INH 2100 U
Number of subjects: 16
Study 28202404 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional doses after initial rhC1-INH 2100 U dose (total dose, 4200-6300 U)
Number of subjects: 16
Study 28202404 — intervention group
Group type: EXPERIMENTAL
Intervention: rhC1-INH
Number of subjects: 16
Study 26272170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on the day of separation
Number of subjects: 40
Study 26272170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 40
Study 23742176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 81
Study 21525161 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol 0.05 mg/d
Number of subjects: 72
Study 21525161 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem 10 mg/d
Number of subjects: 72
Study 21525161 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 18594905 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stents
Number of subjects: 1475
Study 18594905 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered metallic stents
Number of subjects: 1475
Study 18594905 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered metallic stents
Number of subjects: 1475
Study 18594905 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 1475
Study 17178983 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod in combination with meglumine antimoniate
Number of subjects: 119
Study 17178983 — intervention group
Group type: COMPARATOR
Intervention: Placebo with meglumine antimoniate
Number of subjects: 119
Study 14560417 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished surface finish femoral components
Number of subjects: 226
Study 14560417 — intervention group
Group type: COMPARATOR
Intervention: Grit-blasted surface finish femoral components
Number of subjects: 226
Study 14560417 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished and grit-blasted components
Number of subjects: 226
Study 10971314 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent washed spacer
Number of subjects: 20
Study 10971314 — intervention group
Group type: COMPARATOR
Intervention: Untreated new spacer
Number of subjects: 20
Study 8607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 10
Study 8607331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 10
Study 1727882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver sulfadiazine cream applied twice daily to the urethral meatus
Number of subjects: 696
Study 1727882 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 696
Study 1727882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver sulfadiazine cream
Number of subjects: 696
Study 6395321 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (NAP) 10 mg/kg/day
Number of subjects: 80
Study 6395321 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 75 mg/kg/day
Number of subjects: 80
Study 6395321 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (NAP)
Number of subjects: 80
Study 6395321 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 80
Study 30975228 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic Camelina sativa seed oil (CSO)
Number of subjects: 0
Study 30975228 — intervention group
Group type: COMPARATOR
Intervention: Commercial blended fish oil (BFO)
Number of subjects: 0
Study 29451953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization-guided surgical approach
Number of subjects: 248
Study 29451953 — intervention group
Group type: COMPARATOR
Intervention: Non-adjacent-fluorescence visualization margins
Number of subjects: 248
Study 26947697 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylbetaine‐polihexanide (PP) solution (Prontosan)
Number of subjects: 289
Study 26947697 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) solution
Number of subjects: 289
Study 24883449 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on group (prolonged RF application to 90 seconds)
Number of subjects: 131
Study 24883449 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard RF application of 30 seconds)
Number of subjects: 131
Study 22686133 — intervention group
Group type: EXPERIMENTAL
Intervention: Move It Now, a guided self-help intervention via the Internet using cognitive behavioural techniques
Number of subjects: 60
Study 22686133 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 60
Study 21034176 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmycin/Dexamethasone
Number of subjects: 80
Study 21034176 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin/Dexamethasone
Number of subjects: 80
Study 17400980 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteus approach with mepivacaine
Number of subjects: 48
Study 17400980 — intervention group
Group type: COMPARATOR
Intervention: Popliteal approach with mepivacaine
Number of subjects: 48
Study 16372487 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast radiotherapy (WBRT) (40 Gy in 15 fractions)
Number of subjects: 174
Study 16372487 — intervention group
Group type: COMPARATOR
Intervention: Partial-breast irradiation by a variety of techniques
Number of subjects: 174
Study 11696205 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.7 mg/kg, t.i.d.)
Number of subjects: 8
Study 11696205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9390413 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 222
Study 9390413 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of the prophecy
Number of subjects: 222
Study 8198900 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 0.60
Number of subjects: 20
Study 8198900 — intervention group
Group type: EXPERIMENTAL
Intervention: Model B with variable two-compartment relative V/Q mismatch
Number of subjects: 20
Study 8198900 — intervention group
Group type: COMPARATOR
Intervention: Postoperative PaO2 data from other workers
Number of subjects: 20
Study 3241272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic (lactate threshold) exercise therapy for 10 weeks
Number of subjects: 21
Study 3241272 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising hypertensive control group
Number of subjects: 21
Study 3241272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group responders (10 mmHg or more fall in mean blood pressure)
Number of subjects: 21
Study 29189426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (moderate physical activity during routine daily activities)
Number of subjects: 109
Study 29189426 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV-uninfected adults)
Number of subjects: 109
Study 29189426 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive adults
Number of subjects: 109
Study 29189426 — intervention group
Group type: EXPERIMENTAL
Intervention: Current CD4+ T cell count
Number of subjects: 109
Study 26331290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 711
Study 26331290 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 711
Study 26265447 — intervention group
Group type: EXPERIMENTAL
Intervention: CryoSeal® (5 ml per ITA bed)
Number of subjects: 1445
Study 26265447 — intervention group
Group type: COMPARATOR
Intervention: No CryoSeal® (control)
Number of subjects: 1445
Study 23073671 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR prompt for HBV testing
Number of subjects: 175
Study 23073671 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 20941948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-containing spray (1% concentration, low molecular chitosan, degree of deacetylation 87%)
Number of subjects: 29
Study 20941948 — intervention group
Group type: COMPARATOR
Intervention: Chitosan-free control (vehicle only) spray
Number of subjects: 29
Study 18371465 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1 (250 mg/d)
Number of subjects: 3023
Study 18371465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023
Study 16298234 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer disease patients
Number of subjects: 218
Study 16298234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular dementia and dementia of mixed type patients
Number of subjects: 218
Study 16298234 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 218
Study 16298234 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Alzheimer forms of dementia and other neurodegenerative diseases
Number of subjects: 218
Study 16298234 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 218
Study 14750576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment starting at 40 mg/day, tapered by 5 mg every 2 weeks for 16 weeks
Number of subjects: 92
Study 14750576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 10497377 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukostop filter
Number of subjects: 15
Study 10497377 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusion without filter
Number of subjects: 15
Study 10497377 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusion with filter
Number of subjects: 15
Study 8766365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy during psychotherapy stages
Number of subjects: 0
Study 8766365 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 8766365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pharmacotherapy and psychotherapy
Number of subjects: 0
Study 2012511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.3 mg/kg
Number of subjects: 99
Study 2012511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg
Number of subjects: 99
Study 2012511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 6802095 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmole of sodium phosphate at the fourth hour
Number of subjects: 44
Study 6802095 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmole of sodium phosphate at 2, 6, and 10 hours
Number of subjects: 44
Study 6802095 — intervention group
Group type: COMPARATOR
Intervention: No phosphate replacement
Number of subjects: 44
Study 6802095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate therapy
Number of subjects: 44
Study 31401672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) transfer
Number of subjects: 51
Study 31401672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31401672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient cohort (both BMC and placebo)
Number of subjects: 51
Study 29574170 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program with instructions for performing 'the Knack' (n=50)
Number of subjects: 99
Study 29574170 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group, n=49)
Number of subjects: 99
Study 27341675 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Progressive Muscle Relaxation
Number of subjects: 208
Study 27341675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 23906509 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal worry
Number of subjects: 50
Study 23906509 — intervention group
Group type: COMPARATOR
Intervention: Imagery‐based worry
Number of subjects: 50
Study 22250666 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education program (SM), 4-week intervention based on 'Living Well with COPD' program.
Number of subjects: 110
Study 22250666 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), n = 50.
Number of subjects: 110
Study 20413602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-expression profiling
Number of subjects: 602
Study 20413602 — intervention group
Group type: COMPARATOR
Intervention: Routine endomyocardial biopsies
Number of subjects: 602
Study 18779280 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 servings/d of a pistachio diet (2 PD)
Number of subjects: 28
Study 18779280 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 serving/d of a pistachio diet (1 PD)
Number of subjects: 28
Study 18779280 — intervention group
Group type: COMPARATOR
Intervention: lower‐fat control diet with no pistachios
Number of subjects: 28
Study 15714351 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training for three months including back school
Number of subjects: 183
Study 15714351 — intervention group
Group type: COMPARATOR
Intervention: Back school (comparison group)
Number of subjects: 183
Study 12351551 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoculture medium (Rotterdam medium) for 5 days
Number of subjects: 158
Study 12351551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam medium for 3 days followed by fresh Rotterdam medium for 2 days
Number of subjects: 158
Study 12351551 — intervention group
Group type: EXPERIMENTAL
Intervention: G1/G2 sequential culture system for 5 days
Number of subjects: 158
Study 10075143 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 537
Study 10075143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 7669385 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (batch 1)
Number of subjects: 531
Study 7669385 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (batches 2 and 3)
Number of subjects: 531
Study 2187694 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation program
Number of subjects: 119
Study 2187694 — intervention group
Group type: COMPARATOR
Intervention: Education control program
Number of subjects: 119
Study 7362083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Berotec) 0.1% solution, 60 micrograms per nostril every six hours
Number of subjects: 25
Study 7362083 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 25
Study 7362083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Berotec) 0.1% solution, doubled dosage
Number of subjects: 25
Study 6341684 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 100 mg/day for 6 weeks
Number of subjects: 23
Study 6341684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30357394 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC105 and pazopanib
Number of subjects: 0
Study 30357394 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib alone
Number of subjects: 0
Study 29912604 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2000 mg/day)
Number of subjects: 11
Study 29912604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29912604 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 11
Study 27741174 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin plus Aspirin (4,000 IU enoxaparin + 100 mg aspirin)
Number of subjects: 232
Study 27741174 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (100 mg aspirin)
Number of subjects: 232
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin
Number of subjects: 576
Study 25474427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ASA)
Number of subjects: 576
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy (non-ASA)
Number of subjects: 576
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 576
Study 25474427 — intervention group
Group type: EXPERIMENTAL
Intervention: No clopidogrel (non-clopidogrel)
Number of subjects: 576